Sharon Klahre | executive |
Michael Metzger | executive |
Neil Gallagher | executive |
Keith Goldan | executive |
Bradley Canino | analyst |
Ashiq Mubarack | analyst |
Anjali Ganguli | executive |
Philip Nadeau | analyst |
Peter Lawson | analyst |
Michael Schmidt | analyst |
Kalpit Patel | analyst |
Justin Zelin | analyst |
George Farmer | analyst |
Good day, everyone, and welcome to the Syndax Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.At this time, I'd like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, Operator. Welcome, and thank you all for joining us today for a review of Syndax's third quarter 2023 financial and operating results. I'm Sharon Klahre and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr.